Olaparib As Maintenance Therapy In Patients With Platinum-Sensitive Relapsed Ovarian Cancer, BRCA1/2 Mutations Following 2 Or More Prior Platinum Regimens Shows Trend Toward OS

Cancer Network (4/5, Sternberg) reports, “A final analysis of the phase 3 SOLO2 trial (NCT01874353) examining olaparib (Lynarza) tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and BRCA1/2 mutations following 2 or more prior platinum regimens showed a trend toward overall survival (OS) superiority versus placebo maintenance.” The results were published in Lancet Oncology.